<h1 id="overanticoagulation-and-supratherapeutic-inr">Overanticoagulation and Supratherapeutic INR</h1>
<p><strong>ACCP treatment guidelines for managing supratherapeutic INR (2012, 9th ed)</strong></p>
<table>
<thead>
<tr>
<th><strong>INR</strong></th>
<th><strong>Therapeutic intervention</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>â‰¤ 10</td>
<td><em>If no bleeding:</em> Hold <span class="drug">coumadin</span>. Restart when INR is therapeutic</td>
</tr>
<tr>
<td>&gt; 10</td>
<td><em>If no bleeding</em>: Hold <span class="drug">coumadin</span>. Give oral <span class="drug">vitamin K</span> (2.5 mg)</td>
</tr>
<tr>
<td>Major bleed</td>
<td>Hold <span class="drug">coumadin</span>. Give <span class="drug">vitamin K</span> (5-10 mg slow IVP), 4-factor <span class="drug">PCC</span> (<span class="drug">FFP</span> not of added benefit with <span class="drug">PCC</span>)</td>
</tr>
</tbody>
</table>
<p><strong>Higher bleeding risk associated with coumadin</strong></p>
<ul>
<li><em>NSAIDS:</em> non-selective and COX-2 selective</li>
<li><em>Antiplatelet agents</em>: <span class="drug">aspirin</span>, <span class="drug">clopidogrel</span></li>
<li><strong><em>Clotrimoxazole</em></strong></li>
<li><em>Antibiotics</em> (especially fluoroquinolones)</li>
</ul>
<p><strong>Pearl</strong></p>
<ul>
<li>Risk of intracranial hemorrhage doubles for every 1-point increase in INR</li>
</ul>
<h2 id="causes-for-supratherapeutic-inr-gt-6">Causes for supratherapeutic INR &gt; 6</h2>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/9496982">Hylek et al. JAMA 1998 study</a></p>
<ul>
<li>Retrospective case-control study of patients with INR &gt; 6</li>
<li>Enrolled 93 cases, 196 controls</li>
</ul>
<table>
<colgroup>
<col width="50%" />
<col width="50%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk factor/explanation</strong></th>
<th><strong>OR</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Advanced malignancy</td>
<td>16.4</td>
</tr>
<tr class="even">
<td><strong></strong>
<p><span class="drug">Acetaminophen</span> intake  4.5-9.1 g/wk<br />
  &gt; 9.1 g/wk</p></td>
<td><br />
6.8<br />
10</td>
</tr>
<tr class="odd">
<td>New medication</td>
<td>8.5</td>
</tr>
<tr class="even">
<td>Excess <span class="drug">coumadin</span> intake</td>
<td>8.1</td>
</tr>
<tr class="odd">
<td>Decreased oral intake</td>
<td>3.6</td>
</tr>
<tr class="even">
<td>Acute diarrheal illness</td>
<td>3.5</td>
</tr>
<tr class="odd">
<td>Vitamin K intake</td>
<td>0.7</td>
</tr>
<tr class="even">
<td>Alcohol use<br />
(1 drink QOD-2 drinks daily)</td>
<td>0.2</td>
</tr>
</tbody>
</table>

<h2 id="references">References</h2>
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/9496982">Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4;279(9):657-62</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22315259">Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e152S-84S. doi: 10.1378/chest.11-2295.</a></li>
</ul>
